Navigation Links
Panel suggests selling allergy drugs OTC

An advisory committee to the U.S. Food and Drug Administration recommended that three popular allergy drugs are safe enough to be used without a prescription. The FDA does not have to follow the advice of its advisory committee, though it usually does. There is no deadline for making a decision. //

"Drugs are prescription for a reason. They have the ability to do both good and harm. Claritin, Allegra and Zyrtec have almost no side effects and are equally effective as the antihistamines that are available over the counter today." said Robert Seidman, WellPoint's chief pharmacy officer.

Anti-allergy medications have been linked to side effects in some users that include reduced alertness, nausea and headache. By prescription, the drugs cost about $80 per month versus $10 to $15 in the 17 nations where the drugs are over-the-counter. The drug makers oppose a switch, which would cost them money.

Usually, drug companies support making a drug over-the-counter only when their patent is about to run out, because doing so at that time extends the period during which makers of generic drugs are prohibited from selling lower-priced versions of the drug.

Claritin's patent is due to expire in 2002, but the company is waging a multi-million-dollar campaign to get it extended. Aventis Pharmaceuticals, which manufactures Allegra, also expressed its disappointment. According to WellPoint, sales of Allegra, Claritin and Zyrtec exceeded $5 billion last year.
'"/>




Page: 1

Related medicine news :

1. Anti-Quota Stir: Resident Docs Demand Experts Panel
2. Circumcision Studies to Continue Says Health Panel
3. Panel to Help Combat HIV/AIDS In Asia-Pacific Region
4. Breast Cancer Review Panel Adds Two Experts
5. Shingles Vaccine For Older People - Panel Recommendation
6. Complaints Against US Federal lab Over-ruled by Panel
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Generic Biologics – U.S Panel Hearing Draws Mixed Response
9. Expert Panel Sets Limits on Pesticide Residues in Soft Drinks
10. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
11. National Pharmaceutical Policy Referred to Ministerial Panel
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... be asking before selecting an FDA approval pathway? , How should they ...
(Date:2/17/2017)... ... 17, 2017 , ... Corrective Action & Preventive Action for ... Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/capamd      ... action (PA)? , The methods share techniques and tools but they are different ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: